Benlysta Archives - Lupus Research

Tag: Benlysta

LRA Pleased to Share GSK’s Benlysta® (belimumab) is First Lupus Nephritis Treatment Approved by FDA

NEW YORK, NY. December 17, 2020. The Lupus Research Alliance (LRA) congratulates GSK on the U.S. Food and Drug Administration (FDA) approval of belimumab (Benlysta®) as the first-ever treatment specifically indicated for lupus nephritis (LN) in adults. Another milestone, this new indication is the only FDA approval of a new lupus treatment since belimumab was […] Read More

LRA Congratulates GSK on FDA Approval of Benlysta® (belimumab) for Children with Lupus Nephritis

NEW YORK, NY. July 27, 2022. The Lupus Research Alliance (LRA) is pleased to share that the U.S. Food and Drug Administration (FDA) has approved belimumab (Benlysta®) as the first-ever treatment specifically indicated for children aged 5 to 17 with lupus nephritis. Belimumab is already approved by the FDA to treat lupus nephritis in adults […] Read More

Promise of Additional Lupus Therapies Highlighted at ACR 2021 Annual Meeting

November 9, 2021 Results of clinical trials testing many existing and potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR Convergence 2021, November 3-9. Bringing you the most relevant news for our lupus community, following are summaries of key research presented at the meeting: New Data on Approved Lupus Treatments […] Read More

Independent Panel Gives High Marks to New Lupus Nephritis Therapies, Policies Reflect LRA Feedback

April 20, 2021 At a public meeting in March led by the Institute for Clinical and Economic Review (ICER), an independent panel voted unanimously that both belimumab (Benlysta) and voclosporin (Lupkynis), newly approved to treat lupus nephritis, provide a health benefit over standard therapy alone. ICER’s policy recommendations for the use of these two medications […] Read More

LRA Applauds GSK on Positive Phase 3 Study of Benlysta® in Lupus Nephritis

September 16, 2020 NEW YORK, NY. The Lupus Research Alliance welcomes positive BLISS-LN Phase 3 data published in this week’s New England Journal of Medicine, demonstrating that GSK’s drug Benlysta® (belimumab) significantly improved kidney function in adults with lupus nephritis, the most common severe complication of lupus causing inflammation and serious damage to the kidney. The […] Read More

New Data Showed Safety and Effectiveness of Benlysta for Kids

July 27, 2020 A new international study published in Annals of the Rheumatic Diseases showed that belimumab (Benlysta) was safe and effective when given intravenously to children. In this Phase 2, randomized, placebo-controlled, blinded study, 93 patients 5-17 years of age received standard therapy plus either placebo or belimumab. As measured by commonly used tools, […] Read More

Research Shows Benefit to Starting Belimumab Sooner Rather Than Later

April 16, 2020 Treating people with lupus earlier with belimumab (Benlysta) may work better than as a last option according to a study just published in the well-respected journal Arthritis & Rheumatology Researchers in Italy analyzed data from 466 people with lupus at 24 centers in Italy who were receiving belimumab intravenously. They looked at […] Read More

LRA Shares Excitement For What’s Ahead in Lupus Nephritis

January 16, 2020 Up to half of people with lupus will have lupus nephritis – damage to the kidneys that affects the ability to clear the body of wastes and toxins. In 2020, we expect to see significant progress in new drug development for lupus and lupus nephritis in particular with submissions for FDA approval in […] Read More

LRA Celebrates Major Research Breakthroughs in 2019

January 7, 2020 2019 was a phenomenal, breakthrough year for lupus research on both the clinical development and basic science fronts. The Lupus Research Alliance (LRA) is incredibly proud that every new discovery leading to a brand new medicine for lupus had its origin in work funded by LRA years ago. The past 12 months delivered many […] Read More

New Phase 3 Study Shows Positive Results for Benlysta® in Lupus Nephritis

December 17, 2019 The Lupus Research Alliance is thrilled to share exciting news from GSK that Benlysta (belimumab) demonstrated positive clinical trial results in treating lupus nephritis (LN), a common complication of lupus causing inflammation of the kidneys that can result in end-stage kidney disease. Called BLISS-LN, this Phase 3 trial is the largest one […] Read More